It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is ample support for developmental regulation of glioblastoma stem cells. To examine how cell lineage controls glioblastoma stem cell function, we present a cross-species epigenome analysis of mouse and human glioblastoma stem cells. We analyze and compare the chromatin-accessibility landscape of nine mouse glioblastoma stem cell cultures of three defined origins and 60 patient-derived glioblastoma stem cell cultures by assay for transposase-accessible chromatin using sequencing. This separates the mouse cultures according to cell of origin and identifies three human glioblastoma stem cell clusters that show overlapping characteristics with each of the mouse groups, and a distribution along an axis of proneural to mesenchymal phenotypes. The epigenetic-based human glioblastoma stem cell clusters display distinct functional properties and can separate patient survival. Cross-species analyses reveals conserved epigenetic regulation of mouse and human glioblastoma stem cells. We conclude that epigenetic control of glioblastoma stem cells primarily is dictated by developmental origin which impacts clinically relevant glioblastoma stem cell properties and patient survival.
The epigenetic regulation of glioblastoma stem cell (GSC) function remains poorly understood. Here, the authors compare the chromatin accessibility landscape of GSC cultures from mice and patients and suggest that the epigenome of GSCs is cell lineage-regulated and could predict patient survival.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Maturi Naga Prathyusha 2
; Jarvius Malin 3 ; Yildirim Irem 2
; Dang Yonglong 4 ; Zhao Linxuan 1 ; Xie, Yuan 5 ; E-Jean, Tan 6
; Xing Pengwei 1 ; Larsson Rolf 7 ; Fryknäs Mårten 7 ; Uhrbom Lene 2
; Chen, Xingqi 1
1 Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
2 Uppsala University and Science for Life Laboratory, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
3 Uppsala University and Science for Life Laboratory, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Uppsala University, Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
4 Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Karolinska Institutet, Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
5 Uppsala University and Science for Life Laboratory, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Shaanxi Normal University, College of Life Sciences, Xi’an, China (GRID:grid.412498.2) (ISNI:0000 0004 1759 8395)
6 Uppsala University and Science for Life Laboratory, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Department of Organismal Biology, Uppsala University, Norbyvägen 18A, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
7 Uppsala University and Science for Life Laboratory, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)




